US 11,912,755 B2
Endostatin fragments and variants for use in treating fibrosis
Carol Feghali-Bostwick, Mt Pleasant, NC (US); Terence E. Ryan, Eagleville, PA (US); Hal S. Padgett, Vacaville, CA (US); and Matthew McGee, Vacaville, CA (US)
Assigned to Bio, Inc., New York, NY (US); Novici Biotech LLC, Vacaville, CA (US); and MUSC Foundation for Research Development, Charleston (SG)
Filed by iBio, Inc., New York, NY (US); Novici Biotech LLC, Vacaville, CA (US); and MUSC Foundation for Research Development, Charleston, NC (US)
Filed on Nov. 9, 2020, as Appl. No. 17/092,539.
Application 17/092,539 is a continuation of application No. 15/579,690, granted, now 10,844,392, previously published as PCT/US2016/035858, filed on Jun. 3, 2016.
Claims priority of provisional application 62/257,607, filed on Nov. 19, 2015.
Claims priority of provisional application 62/171,889, filed on Jun. 5, 2015.
Prior Publication US 2021/0108221 A1, Apr. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/78 (2006.01); C12N 15/82 (2006.01)
CPC C07K 14/78 (2013.01) [C12N 15/8257 (2013.01); C07K 2319/036 (2013.01); C07K 2319/30 (2013.01)] 4 Claims
 
1. An isolated polypeptide, wherein the polypeptide:
is selected from SEQ ID NO: 15, 16 or 17; and
has anti-fibrotic activity when administered to a subject in need thereof.